ANXA3

Across TCGA pan-cancer cohorts, ANXA3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANXA3 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ANXA3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ANXA3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where ANXA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	1.000	0.451	.016	20	view →
LUAD	OS	Tertile	III,IV	0.225	1.000	.002	19	view →
PDAC	OS	Median	All	0.702	0.939	.012	14	view →
UCEC	DFS	Tertile	II,III,IV	0.889	0.408	.018	12	view →
LSCC	DFS	Tertile	All	0.880	0.964	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANXA3–CCRCC (OS)

Open the CCRCC breakdown →